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Guest Editorial
ALLHAT: More Answers or Questions?
RAYMOND KIN-MAN MIU, CHU-PAK LAU, HUNG-FAT TSE
From Cardiology Division, Department of Medicine, Queen Mary Hospital, The University of Hong Kong,
Hong Kong

Hypertension is one of the most important
preventable causes of premature death worldwide.
Although lowering of blood pressure by antihypertensive agents have been shown to reduce
morbidity and mortality in major clinical trials, the
optimal antihypertensive agent remains unclear. The
recently completed and published Antihypertensive and
Lipid-Lowering Treatment to Prevent Heart Attack Trial
(ALLHAT)1 was the largest trial of antihypertensive
therapy ever conducted. ALLHAT is also the first
clinical trial that designed to compare different
antihypertensive agents for prevention of coronary heart
disease (CHD) with the combined incidence of fatal
CHD and non-fatal myocardial infarction as the primary
endpoint. Since the publication of the results of
ALLHAT, there has been intense debate across the
medical community about its implications. What is the
clinical implication of the results of ALLHAT on our
clinical practice in treating patients with hypertension,
and are their findings applicable to the local Chinese
population?
ALLHAT randomized 42,418 patients with mild
to moderate hypertension aged >55 years old and at least
one additional cardiovascular risk factors to one of four
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antihypertensive treatment: the diuretic chlorthalidone
(12.5-25 mg daily), the angiotensin converting enzyme
(ACE) inhibitor lisinopril (10-40 mg daily), the calcium
channel blocker amlodipine (2.5-10 mg daily) or the
α blocker doxazosin (1-8 mg daily). 1 This study
included a higher percentage of women (47%), black
Americans (35%) and patients with diabetes (36%). The
doxazosin arm was terminated prematurely due to an
excess of congestive heart failure. After a mean followup of 4.9 years, there was no difference in the primary
outcome between treatment with chlorthalidone
(11.5%), lisinopril (11.4%), amlodipine (11.3%). The
ALLHAT investigators concluded that the thiazide-like
diuretic is the preferred approach for the initial
management of hypertension as it is no inferior to the
other therapeutic classes in the primary outcome, but is
less expensive. Furthermore, thiazide-like diuretic is
more effective in blood pressure control and even
superior than the other therapeutic classes on other
outcome, such as congestive heart failure and stroke.1
However, there are some major flaws in the study
design of ALLHAT. First, ALLHAT did not study the
initiation of treatment which it was supposed to be.
Rather, 90% of patients in ALLHAT were "roll-over"
from previous treatment with no idea of their real
starting blood pressure.2,3 Ideally, there should have been
a wash-out period to establish the baseline blood
pressure. Second, there was partial and complete
crossover of therapy in up to 20-25% of the study
patients, which could potentially diminish the
differences between the study drugs in an intention-totreat analysis.2,3 Third, up to 63% of patients in the study
required two or more drugs to control blood pressure to
the target level. The illogical combination of second
step drugs (atenolol, clonidine and reserpine) made
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certain drug combination which both targeted the reninangiotensin system (e.g. ACE inhibitor and betablocker) in an unfavourable position in blood pressure
control. As a result, the groups treated with amlodipine
and lisinopril did not achieve the same level of blood
pressure control as chlorthalidone group. The final
systolic blood pressure difference, albeit small, of
2 mmHg and of 0.8 mmHg in lisinopril and amlodipine
group, respectively compared with chlorthalidone can
account for the differences in the outcome in this large
clinical trial. As a result, ALLHAT did not tell us the
right combination of anti-hypertensive agents which
could have a significant impact on the blood pressure
lowering efficacy or cardiovascular outcome. In the
LIFE study,4 a losartan-based therapy together with a
thiazide-type diuretics excelled in major cardiovascular
outcome when compared with an atenolol-based
therapy. Finally, in a subgroup of black people in which
ACE inhibitor is well known to be less effective, a blood
pressure disadvantage of 4 mmHg in the ACE inhibitor
group was translated into a 40% increase in stroke risk
when compared with diuretics.1
Furthermore, there is a major controversy about
the interpretation of ALLHAT. The ALLHAT
investigators concluded that a thiazide-type diuretics
was more superior in reducing one or more major forms
of cardiovascular disease over the ACE inhibitor and
the calcium channel blocker.1 However, this statement
was primarily driven by a higher incidence of heart
failure in the ACE inhibitor group and the calcium
channel blocker group which was not a prespecified
secondary end-point of the study. Indeed this finding
goes in opposite direction to the meta-analysis of
previous trials (Blood Pressure Lowering Treatment
Trialists' Collaboration) 5 and a recent prospective
clinical study (ANBP2)6 that compared the incidence
on heart failure of diuretics-based treatment with ACE
inhibitor. In ALLHAT, congestive heart failure is
diagnosed clinically by the primary-care physicians. It
is possible that treatment with diuretics masked the signs
of fluid-retention signs and might have led the
investigators to the incorrect diagnosis. Moreover, the
details on prior medication were not reported in
ALLHAT.1 It is probably a certain number of patients
who were on diuretics were suddenly switched to the
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calcium channel blocker or ACE inhibitor which might
contribute to fluid retention leading to an incorrect
diagnosis of congestive heart failure. From the KaplanMeier curves of the study, it is evident that the difference
in incidence of congestive heart failure occurred almost
immediately after randomization and that the curves ran
parallel at least up to the fourth year.
The ALLHAT investigators also ignore the
potential long-term metabolic side-effects of diuretics.1
They had implied that dyslipidemia, hypokalemia and
new onset diabetes, which were more common among
patients taking diuretics were not of clinical concern
because they had no bearing on the final cardiovascular
outcome. In particularly, considerably more patients
developed new-onset diabetes in the chlorthalidone
group (11.6%) than in the amlodipine (9.8%) and
lisinopril (8.1%). However, the cardiovascular risk
incurred over a 5-year period in the trial could not
automatically assumed to be the same as the general
population whom we are treating for a much longer
period of time. In ALLHAT, there was no excess of
sudden cardiac deaths (presumably due to arrhythmia)
or all cause mortality in the diuretics arm, which
apparently had negated the fear of electrolyte
disturbance. It is well known that the Chinese diet is
relatively deficient of potassium. Prior studies have
demonstrated that the serum potassium concentrations
in Chinese population is lower than those in Caucasian
(3.82 mmol/L vs. 4.38 mmol/L),7 In our local population,
the use of diuretic for treatment of hypertension was
associated a high prevalence of hypokalaemia.8 Whether
our local Chinese population being put on a diureticbased therapy would fair equally well in cardiovascular
mortality and morbidity outcome over the long term as
the Caucasian remains unknown. Furthermore, it might
not be correct to assume the efficacy and side-effect
profile of the different thiazide-like diuretics
(chlorthalidone, hydrochlorothiazides and indapamide)
are equivalent,6 which we based heavily on the latter
two agents in our clinical practice at least in the
government out-patient clinic.
Finally, the major consequence of hypertension
in the Chinese population is stroke rather than CHD. In
both ALLHAT1 and large meta-analysis (Blood Pressure
Lowering Treatment Trialists' Collaboration),4 there was
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a trend in favour of the calcium channel blocker for
prevention of stroke. Therefore, calcium channel
blocker may be more useful in Chinese patients with
hypertension.
In summary, the results of ALLHAT do not
provide us a clear answer to which agents should be
used as first-line treatment for hypertension nor the ideal
combination of drugs to achieve optimal blood pressure
control. In this regard, the coming data from ASCOT
(randomized treatment of a beta-blocker with or without
diuretic vs. a calcium channel blocker with or without
an ACE inhibitor) are awaited with interest.9 However,
this largest ever randomized hypertension trial have
informed us that what matters most in managing
hypertension is getting blood pressure controlled rather
than which specific class of agents used. In the majority
of patients, combination of several drugs will be
required and the use of a low dose thiazide diuretic
should be included.
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